| Expression of CD5 in salivary gland tumors: an ancillary marker for carcinoma showing thymus-like differentiation (CASTLE) of the major salivary gland. | Expression of CD5 in salivary gland tumors: an ancillary marker for carcinoma showing thymus-like differentiation (CASTLE) of the major salivary gland.
Sasaki E, Terada H, Oishi N, Iwakoshi A, Masago K, Matsushita H, Yamamoto H, Hanai N, Tateyama H. | 06/28/2024 |
| CD5: from antiquated T cell marker to immunotherapy's new hope. | CD5: from antiquated T cell marker to immunotherapy's new hope.
Schwarz S, Linnebacher M., Free PMC Article | 06/12/2023 |
| CD5 Suppresses IL-15-Induced Proliferation of Human Memory CD8(+) T Cells by Inhibiting mTOR Pathways. | CD5 Suppresses IL-15-Induced Proliferation of Human Memory CD8(+) T Cells by Inhibiting mTOR Pathways.
Choi YJ, Lee H, Kim JH, Kim SY, Koh JY, Sa M, Park SH, Shin EC. | 10/8/2022 |
| Gene variation impact on prostate cancer progression: Lymphocyte modulator, activation, and cell adhesion gene variant contribution. | Gene variation impact on prostate cancer progression: Lymphocyte modulator, activation, and cell adhesion gene variant contribution.
Casadó-Llombart S, Ajami T, Consuegra-Fernández M, Carreras E, Aranda F, Armiger N, Alcaraz A, Mengual L, Lozano F., Free PMC Article | 09/3/2022 |
| T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape. | T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape.
Dai Z, Mu W, Zhao Y, Cheng J, Lin H, Ouyang K, Jia X, Liu J, Wei Q, Wang M, Liu C, Tan T, Zhou J., Free PMC Article | 04/23/2022 |
| 14-Color single tube for flow cytometric characterization of CD5+ B-LPDs and high sensitivity automated minimal residual disease quantitation of CLL/SLL. | 14-Color single tube for flow cytometric characterization of CD5+ B-LPDs and high sensitivity automated minimal residual disease quantitation of CLL/SLL.
Goshaw JM, Gao Q, Wardrope J, Dogan A, Roshal M., Free PMC Article | 01/8/2022 |
| Clinical and biological features of B-cell neoplasms with CDK6 translocations: an association with a subgroup of splenic marginal zone lymphomas displaying frequent CD5 expression, prolymphocytic cells, and TP53 abnormalities. | Clinical and biological features of B-cell neoplasms with CDK6 translocations: an association with a subgroup of splenic marginal zone lymphomas displaying frequent CD5 expression, prolymphocytic cells, and TP53 abnormalities.
Gailllard B, Cornillet-Lefebvre P, Le QH, Maloum K, Pannetier M, Lecoq-Lafon C, Grange B, Jondreville L, Michaux L, Nadal N, Ittel A, Luquet I, Struski S, Lefebvre C, Gaillard JB, Lafage-Pochitaloff M, Balducci E, Penther D, Barin C, Collonge-Rame MA, Jimenez-Poquet M, Richebourg S, Lemaire P, Defasque S, Radford-Weiss I, Bidet A, Susin SA, Nguyen-Khac F, Chapiro E, Groupe Francophone de Cytogénétique Hématologique. | 09/25/2021 |
| Contribution of Evolutionary Selected Immune Gene Polymorphism to Immune-Related Disorders: The Case of Lymphocyte Scavenger Receptors CD5 and CD6. | Contribution of Evolutionary Selected Immune Gene Polymorphism to Immune-Related Disorders: The Case of Lymphocyte Scavenger Receptors CD5 and CD6.
Casadó-Llombart S, Velasco-de Andrés M, Català C, Leyton-Pereira A, Lozano F, Bosch E., Free PMC Article | 06/19/2021 |
| diffuse large B-cell lymphoma (DLBCL) patients with DECM showed significantly inferior clinical outcomes compared to the CD5(+), MYC(+) or CD5(-)MYC(-) patients. Combinational therapeutic modalities might be a candidate approach to improve the prognosis of these patients. | CD5(+)MYC(+) predicts worse prognosis in diffuse large B-cell lymphoma.
Lu TX, Wu S, Zhou XY, Zhang Y, Hong TT, Cai DY, Hua HY, Qi XW, Wu XH. | 07/18/2020 |
| Two different anti-CD5- chimeric antigen receptors with costimulators 4-1BB and 2B4 (referred to as BB.z-natural killer (NK) cells and 2B4.z-NK, respectively) were constructed. 2B4.z-NK cells exhibited rapid proliferation and higher anti-malignant efficacy in both malignant CD5+ cell lines and primary CD5+ malignant cells in vitro through upregulation of activation markers and cytotoxic granule release. | 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies.
Xu Y, Liu Q, Zhong M, Wang Z, Chen Z, Zhang Y, Xing H, Tian Z, Tang K, Liao X, Rao Q, Wang M, Wang J., Free PMC Article | 06/20/2020 |
| Study of four cases of pleomorphic mantle cell lymphoma with an immunophenotype of CD5(-) cyclin D1(-) SOX11(+) and morphologic features compatible with diffuse large B-cell lymphoma. | Identification of CD5/Cyclin D1 Double-negative Pleomorphic Mantle Cell Lymphoma: A Clinicopathologic, Genetic, and Gene Expression Study.
Chuang WY, Chang ST, Yuan CT, Chang GJ, Chang H, Yeh CJ, Ueng SH, Kao HW, Wang TH, Wan YL, Shih LY, Chuang SS, Hsueh C. | 05/16/2020 |
| CD5 was found to promote T cell survival by protecting autoreactive T cell from activation-induced cell death, to promote de novo induction of regulatory T cells in the periphery, to modulate Th17 and Th2 differentiation, and to modulate immune responses by modulating dendritic cell functions. (Review) | The multiple faces of CD5.
Burgueño-Bucio E, Mier-Aguilar CA, Soldevila G. | 05/9/2020 |
| Patients with CD5- Mantle cell lymphoma have a more favorable prognosis than patients with CD5+ MCL. | CD5-negative Mantle Cell Lymphoma: Clinicopathologic Correlations and Outcome in 58 Patients.
Miao Y, Lin P, Saksena A, Xu J, Wang M, Romaguera J, Yin CC, Medeiros LJ, Li S. | 03/28/2020 |
| 30 of 80 CD5-positive patients had p53 overexpression. The OS and PFS of p53-positive, CD5-negative patients were significantly better than those of patients positive for both p53 and CD5, which indicated that the poor survival trend of patients with p53 overexpression might be influenced by CD5 expression.augments the negative effect of p53 overexpression in DLBCL. | CD5 expression correlates with inferior survival and enhances the negative effect of p53 overexpression in diffuse large B-cell lymphoma.
Zhao P, Li L, Zhou S, Qiu L, Qian Z, Liu X, Meng B, Zhang H. | 11/23/2019 |
| our data indicate that DLBCL patients with CD5/CD43 coexpression represent a specific subgroup with a significantly worse prognosis than those expressing either marker alone. | Coexpression of CD5 and CD43 predicts worse prognosis in diffuse large B-cell lymphoma.
Ma XB, Zhong YP, Zheng Y, Jiang J, Wang YP., Free PMC Article | 11/16/2019 |
| siRNAs for CD5 or for TRPC1 inhibit IL-10 production. | CD5 expression promotes IL-10 production through activation of the MAPK/Erk pathway and upregulation of TRPC1 channels in B lymphocytes.
Garaud S, Taher TE, Debant M, Burgos M, Melayah S, Berthou C, Parikh K, Pers JO, Luque-Paz D, Chiocchia G, Peppelenbosch M, Isenberg DA, Youinou P, Mignen O, Renaudineau Y, Mageed RA., Free PMC Article | 05/18/2019 |
| the present results support the notion that CD5 is not only a phenotypic marker but a relevant player in CLL cell biology, as demonstrated by the influence of germline-defined functional CD5 variants on CLL outcome. | Impact of the functional CD5 polymorphism A471V on the response of chronic lymphocytic leukaemia to conventional chemotherapy regimens.
Delgado J, Bielig T, Bonet L, Carnero-Montoro E, Puente XS, Colomer D, Bosch E, Campo E, Lozano F., Free PMC Article | 02/24/2018 |
| ZAP70 is the only gene that is differentially expressed in CD5-high and CD5-low normal B-lymphocytes, confirming the key role of Zap-70 tyrosine kinase in BCR signaling alterations in B-CLL. | Comparison of the mRNA expression profile of B-cell receptor components in normal CD5-high B-lymphocytes and chronic lymphocytic leukemia: a key role of ZAP70.
Gladkikh AA, Potashnikova DM, Tatarskiy V Jr, Yastrebova M, Khamidullina A, Barteneva N, Vorobjev I., Free PMC Article | 02/3/2018 |
| The high CD5 plasma levels in patients with severe ASD, probably indicated that CD5 might be implicated in the physiology of autism. However, this finding should be treated with caution until further investigations are performed with larger populations to determine whether the increase in plasma CD5 levels is a mere consequence of autism or it plays a pathogenic role in the disease. | Cluster of Differentiation 5 (CD5) Levels in the Plasma of Children with Autism Spectrum Disorder (ASD).
Halepoto DM, Alhowikan AM, Ayadhi LA. | 01/20/2018 |
| A CD34-negative MYC-rearranged B-lymphoblastic lymphoma aberrantly expresses CD3 and CD5. | A CD34-negative MYC-rearranged B-lymphoblastic lymphoma aberrantly expresses CD3 and CD5.
Wang HY, Thorson JA. | 01/20/2018 |
| study provides understanding of the regulation of CD5 expression on leukaemic T cells, and may help in understanding the molecular mechanism of CD5 down-regulation. | Exonal switch down-regulates the expression of CD5 on blasts of acute T cell leukaemia.
Rai AK, Singh A, Saxena A, Seth T, Raina V, Mitra DK., Free PMC Article | 11/25/2017 |
| CD5 transcription is increased, leading to the production of three mRNA isoforms by APA, all contributing for protein production, at different levels. PTBP1 binds in the vicinity of pA1, leading to an increase in mRNA levels and miR-204 targets the longer CD5 mRNA. | CD5 expression is regulated during human T-cell activation by alternative polyadenylation, PTBP1, and miR-204.
Domingues RG, Lago-Baldaia I, Pereira-Castro I, Fachini JM, Oliveira L, Drpic D, Lopes N, Henriques T, Neilson JR, Carmo AM, Moreira A., Free PMC Article | 07/1/2017 |
| High CD5 expression is associated with lymphoma in Waldeyer ring. | IFR4/MUM1-positive lymphoma in Waldeyer ring with co-expression of CD5 and CD10.
Chen L, Al-Kzayer LF, Liu T, Kobayashi N, Nakazawa Y, Koike K. | 06/24/2017 |
| Thus, trans-signaling of IL-6 can only occur via sIL-6R, but not sCD5. | Trans-signaling of interleukin-6 (IL-6) is mediated by the soluble IL-6 receptor, but not by soluble CD5.
Aparicio-Siegmund S, Deseke M, Lickert A, Garbers C. | 06/10/2017 |
| The major proportion of CD5(low) B cells in patients are leukemic, thus identifying CD5(low) B cells as an important component of CLL, with implications for CLL pathogenesis, clinical monitoring, and the development of anti-CD5-directed therapies. | Dynamic variation of CD5 surface expression levels within individual chronic lymphocytic leukemia clones.
Bashford-Rogers RJ, Palser AL, Hodkinson C, Baxter J, Follows GA, Vassiliou GS, Kellam P., Free PMC Article | 06/10/2017 |